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Abstract
Introduction: Contrast-induced nephropathy (CIN) is 
associated with increased risk of in-hospital morbidity 
and mortality. The purpose of this study was to find out 
whether continuous venovenous hemofiltration (CVVH) 
after coronary angiography in chronic kidney disease 
(CKD) patients is associated with a lower incidence of 
CIN than that reported in the literature.  
Methods: All patients with CKD who underwent 
coronary angiography in the Chest Disease Hospital, 
Kuwait, between January 2004 and December 2005 were 
treated by CVVH after the procedure. Renal function was 
assessed before and after the procedure. 
Results: A total of 98 patients were enrolled in the study, 
52 (53.1%) of whom were males. Their mean age was 60.7 
years. Before the procedure, the mean serum creatinine 
level was 4.65 mg/dl and the mean creatinine clearance 
(Cr Cl) was 18.04 ml/min. Patients underwent CVVH for 
a mean duration of 21.3 hours, after a mean time-interval 
of 44.3 min. Their mean serum creatinine was 4.57  mg/
dl at discharge (within the first week after the procedure) 
and 4.78 mg/dl at 15 days after the procedure. Mean Cr 
Cl was 18.52 ml/min at discharge and 17.62 ml/min at 
15 days after the procedure. There was no statistically 
significant difference between the mean serum creatinine 
and Cr Cl values before and after the procedure. However, 
one patient (1.02%) developed CIN and ended on regular 
hemodialysis. The in-hospital mortality was 0%. 
Conclusion: Patients with advanced CKD  who undergo 
coronary angiography  may be protected from further 
deterioration in their renal function after exposure 
to radiological contrast material if the procedure is 
immediately followed by CVVH.  A randomized controlled 
clinical trial is needed to verify our encouraging results.
Keywords: contrast induced nephropathy, chronic kidney 
disease, continuous venovenous hemofiltration
Introduction
The incidence of contrast induced nephropathy (CIN) is 
now increasing, owing  to the growing use of radiocontrast 
media (CM) in diagnostic as well as interventional 
procedures [1]. The most widely accepted definition 
of CIN is an increase of 25% or more, or an absolute 
increase of 0.5 mg/dl or more in serum creatinine from 
base line values at 24-72 hours following exposure to 
CM [2]. CIN is one of the leading causes of hospital 
acquired acute renal failure (ARF) and is associated with 
increased morbidity and mortality [3].
Among all procedures utilizing CM for diagnosis 
or therapeutic purposes, coronary angiography and 
percutaneous coronary intervention (PCI) are associated 
with the highest incidence of CIN [1]. The overall 
incidence of CIN in the general population is reported 
to be 0.6-2.3% [4]. However, in several patient subsets 
the prevalence of CIN is significantly higher [5, 6]. The 
incidence of CIN in patients with underlying chronic 
kidney disease (CKD) is extremely high, ranging from 
14.8% to 55% [6-8]. The higher the base-line creatinine 
value, the greater is the risk of CIN [9]. Nevertheless, 
an increasing number of patients with CKD are being 
referred for PCI, owing to the greater prevalence of 
cardiovascular diseases among this group of patients 
[10]. CIN is a potentially reversible condition, however, 
currently available strategies, such as hydration and 
the use of N-acetylcysteine, mannitol, furosemide, 
dopamine, fenoldopam, or other renoprotective drugs 
have been variably shown to be effective in patients 
with normal or mildly impaired renal function [11, 
12]. Methods for prevention of CIN in patients with 
advanced renal failure remain unknown.  Additionally, 
prophylactic hemodialysis, started immediately after the 
administration of CM to this group of patients didn’t 
show any benefit in CIN prevention [13]. 
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Continuous venovenous hemofiltration (CVVH) is an 
alternative strategy to HD for prevention of CIN in high 
risk patients [14, 15].
The purpose of this study was to test the efficacy of 
prophylactic CVVH in the prevention of CIN in patients 
with advanced CKD.
Methods  
A prospective single center study was conducted in 
Chest Disease Hospital of Kuwait from January 2004 
to December 2006. All patients with CKD who were 
scheduled for PCI were included in the study. Inclusion 
criteria were age above 25 years, stable serum creatinine 
concentration above 3.39 mg/dl and creatinine clearance 
less than 35 ml/min within one month prior to the 
procedure. Exclusion criteria were presentation with 
cardiogenic shock, pregnancy, lactation, contraindications 
to heparinization, intravascular administration of 
contrast media or exposure to nephrotoxic drugs 
during the previous two weeks, use of non-steroidal 
anti-inflammatory drugs during the previous 48 hours, 
renal transplantation and, patients with end stage renal 
disease (ESRD) requiring regular dialysis. Angiotensin 
converting enzyme inhibitors were held on the day of the 
procedure. Acetylcysteine, mannitol and dopamine, were 
not used during the procedure. All patients gave a written 
informed consent. 
Patients were started on CVVH as soon as possible 
after the procedure, and the time interval from contrast 
exposure to initiation of dialysis was recorded. CVVH 
was performed through a double lumen intravenous 
femoral catheter (Quinton, Bothell, WA) placed by the 
attending nephrologists before the procedure. CVVH for 
18-24 hours was started using Prisma continuous fluid 
management system (Gambro Lakewood Co.) using 
M100 dialyzer sets (AN69 membrane), with surface 
area of 0.90 m2 and with bicarbonate buffered solution 
for continuous renal replacement therapy (CRRT) from 
Hospal with the following solute composition in mmol/l: 
calcium 1.75, magnesium 0.5, sodium 140, chloride 109.5, 
lactate 3, bicarbonate 32. Blood flow rate was set at 100 
ml/min, and the substitution fluid rate was 2 liters/ hour 
without any additional fluid removal. Anticoagulation 
was achieved by giving heparin bolus of 500 IU at the 
start of CVVH then constant heparin infusion to maintain 
activated partial thromboplastin time between 130-150 
seconds. 
Table 1: Baseline patients' morbidity characteristics (n=98)
Pathology Notes Number (%)
Diabetes mellitus 79 (80.6)
Hypertension 82 (83.7)
Previous myocardial infarction 23 (23.7)
Procedure Diagnostic 19 (19.39)
PCI* 79 (80.61)
Coronary artery disease Normal vessels 3 (3.06)
Single vessel 5 (5.1)
Two vessels 28 (28.57)
Three or more vessels 62 (63.26)
*PCI: percutaneous coronary intervention
Table 2: Baseline patients'  important measurements that may affect renal outcome after cardiac catheterization  (n=98)
Mean (± SD) Range
Age  (years) 60.7 ±10.99 36-81
Body mass index (kg/m2) 28.39 ± 4.71 34-55
Baseline  serum creatinine (mg/dl) 4.65 ± 0.9 3.4 - 7.1
Baseline creatinine clearance (ml/min) 18.04 ± 4.26 12.23-31.09
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Blood urea nitrogen (BUN) and serum creatinine 
were measured before the procedure, at the end of the 
CVVH session, then daily for the following three days, 
at hospital discharge, and 15 days after the day of the 
procedure. Creatinine clearance (Cr Cl) was calculated at 
the same times using Cockcroft and Gault equation [16]. 
the incidence of contrast nephropathy, defined as more 
than 25% increase from  baseline serum creatinine values 
within two weeks after the procedure was calculated. 
Emergency CRRT was performed if there was oliguria 
for more than 48 hours despite administration of more 
than 1 gram of furosemide over 24 hours, or if there 
was evidence of congestive heart failure, or if serum 
potassium was above 6 mmol/l. CRRT was discontinued 
when there was evidence of recovery of renal function 
with the restoration of urine output of more than 500 ml/
day. The need for permanent hemodialysis was defined 
as persistent Cr Cl less than 5 ml/min. The incidence of 
CIN, in hospital mortality, and the need for long term 
dialysis was calculated.
Data were analyzed using SPSS for windows version 
13 (SPSS, Inc, Chicago, IL). Continuous variables were 
expressed as mean ± SD, whereas categorical variables 
were expressed as frequencies and percentages.
Results
A total of 98 patients were enrolled in the study, 52 (53.1%) 
of whom were males, and 46 (46.9%) were females. 
Baseline patients' clinical and measurable indicators that 
may affect renal outcome after cardiac catheterization 
are summarized  (Tables 1 and 2). Seventy nine patients 
(80,6%) were diabetic and 82 (83.7%) were hypertensive. 
Almost a quarter of them (23.7%) had history of previous 
myocardial infarction and cardiac catheterization showed 
that 62 patients (63%) had three vessel disease or more. 
Pre-procedure serum creatinine ranged from 3.42 – 7.14 
mg/dl with a mean of 4.65 ± 0.9 mg/dl, pre-procedure 
Cr Cl ranged from 12.23-31.09 ml/min, with a mean of 
18.04 ± 4.26 ml/min. 
All patients were subjected to post-procedure CVVH. 
The mean time interval between the procedure and the 
start of CVVH was 44.3 ± 18.8 min. The mean duration 
of the session was 21.3 ± 2.1 hours. None of the studied 
subjects had femoral catheter related complications, 
three patients (3.06%) required catheter replacement for 
clotting. The CVVH course was smooth without intra-
procedural complications.  The mean serum creatinine 
after CVVH was 1.62 ± 0.46 mg/dl, 3.51 ± 0.52 mg/dl 
48 hours after the procedure, 4.5 ± 0.71 mg/dl 72 hours 
after the procedure, 4.57 ± 1.0 mg/dl at time of discharge, 
and 4.78 ± 1.0 mg/dl 15 days after the procedure (Figure 
1). There were no statistically significant differences 
between any of the mean post-procedural serum creatinine 
values and the mean pre-procedural serum creatinine. 
Regarding Cr Cl, its mean value was 18.52 ± 4.61 ml/min 
at the time of discharge and 17.62 ± 4.27 ml/min at 15 
days after the procedure (Figure 2). One patient (1.02%) 
developed CIN that required repeated CVVH sessions 
during hospitalization and ended up on regular long term 
hemodialysis. The in-hospital mortality was 0%.
Discussion
Patients with CKD have a predisposition to accelerated 
atherosclerosis; they thus represent an increasing 
percentage of the patients undergoing PCI [17]. The 
clinical outcome of patients in whom CIN develops 
after PCI is particularly poor, with a reported in hospital 
mortality rate of more than 20 percent and cumulative one 
year mortality rate of more than 35 percent [3, 18-21]. 
Mortality even increases to 45-62 percent if dialysis 
was required [19, 21]. Given the clinical and prognostic 
implications, strategies to reduce the incidence of CIN 
are needed particularly in high risk patients [22]. Several 
strategies have been evaluated for the prevention of 
CIN. Among these strategies, only saline hydration [23, 
24], the use of low-osmolality contrast agents [25] and 
treatment with N-acetylcysteine [26-28] or fenoldopam 
[29, 30] have been shown to provide some protection and 
to reduce the incidence of CIN. However, the efficacy of 
these measures is still controversial in patients with severe 
renal impairment [27]. The pharmacokinetic properties 
of water soluble iodinated CM are such that they are 
distributed in the extracellular fluid only, are minimally 
protein bound, are not metabolized, and are excreted 
mainly by the glomerular filtration [31]. In normal 
subjects, elimination of CM takes place rapidly: after 
two hours approximately 50% of the CM is recovered in 
urine. In subjects with severe CKD, the same 50% will be 
eliminated in urine 16-84 hours after injection of the CM 
[32]. Considering the properties of the iodinated CM, 
it was hypothesized that it can be removed by dialysis. 
Our study showed that doing CVVH as soon as possible 
after contrast injection in patients with CKD reduced 
the incidence of CIN to 1.02% in this high risk group of 
patients. This percentage is significantly less than what 
has been reported in the literatures when other preventive 
strategies such as saline hydration or N-acetylcysteine 
were used in patients with CKD. Our results are in 
accordance with previous studies [33-36]. 
Hemodialysis (HD) and hemofiltration (HF) have 
both been studied for the prevention of CIN. To date, 
there have been few trials evaluating hemodialysis for 
prevention of CIN [37, 38]. Hemodialysis and CVVH 
both effectively remove iodinated CM from the blood 
[39]. Despite this, a recent systemic review of studies 
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comparing the periprocedural HD with conventional 
prophylactic measures found that HD did not  decrease 
the risk or the need for acute dialysis following CIN [36]. 
CVVHF and continuous venovenous hemodiafiltration 
(CVVHDF) have also been studied for the prevention 
of CIN after PCI in patients with CKD [36]. In 2003, 
Marenzi et al reported the superiority of CVVH over 
saline hydration in prevention of CIN after PCI in 
patients with CKD, where CIN was reported in 5% of 
the CVVH group versus 50% in the control group [34]. 
Gabutti et al studied the effect of (CVVHDF) performed 
during and after PCI in patients with CKD and concluded 
that CVVHDF is not effective in prevention of CIN [40]. 
Marenzi et al compared the use of saline hydration with 
the use of pre- and post-procedure CVVH or the use 
of post-procedure CVVH and concluded that pre- and 
post-procedure CVVH was superior to the other two 
strategies [35]. On the other hand, Vogt et al didn't show 
any beneficial effect of prophylactic HD for 3 hours after 
the procedure [13]. Moreover, patients who received HD 
were more likely to have a decline in renal function and 
required additional HD treatment. A possible explanation 
for these results is that HD can induce hypovolemia 
and consequently may worsen renal ischemic injury, 
delay recovery of renal functions, and result in a need 
for prolonged dialysis [41]. On the other hand, CVVH 
is associated with hemodynamic stability, allows better 
hydration and regulation of volume status, allows infusion 
of large volume of bicarbonate containing solution, and 
allows removal of CM from the circulation with a resultant 
reduction in the kidneys' exposure to CM [14, 15, 42, 43]. 
In addition, heparin used during the procedure of CVVH 
may have a beneficial effect as it may inhibit acute 
inflammation, attenuate the ischemic reperfusion injury, 
and reduce the oxidative stress that may be involved in 
the pathogenesis of CIN [44, 45]. Lastly, considering 
the relatively high cost and the time-consuming nature 
of CVVH, the limited availability of intensive care unit 
(ICU) beds and the lengthy immobilization of patients 
during CVVH, this procedure should be restricted to the 
high risk patients.
Conclusion
Despite CVVH being expensive, invasive, and time 
consuming, it may have a beneficial effect in preventing 
CIN after PCI in high risk patients with advanced CKD. 
CVVH should be considered as a preventive strategy for 
CIN after PCI in such patients. A randomized controlled 
clinical trial is needed to verify our encouraging results.
Limitations of the study
There was no control group, and the effect of CVVH was 
not compared with the conventional hydration protocols. 
This study was conducted in a single center and the 
results may not be generalizable to other centers. CVVH 
washes out creatinine, and may mask a transient rise in 
serum  creatinin if such a rise was limited to the first 2-3 
days after the procedure. 
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